# Clinical Outcomes of Adalimumab in Rheumatoid Arthritis

## Adalimumab achieves sustained clinical effectiveness in rheumatoid arthritis
Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment.

## Abstract
Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment. Combination therapy with methotrexate substantially outperforms monotherapy, achieving 80% ACR50 responses at 10 years versus 69% with adalimumab alone, and preventing radiographic progression more effectively (modified total Sharp score change of 4.0 versus 8.8 points).

## Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

## Results
### Characteristics of Included Studies
The review included 10 studies evaluating adalimumab in rheumatoid arthritis patients, with study durations ranging from 12 weeks to 10 years.

| Study | Full text retrieved? | Study Type | Patient Population | Disease Duration | Baseline Disease Activity | Treatment Regimen | Duration | Setting |
|-------|---------------------|------------|--------------------|------------------|------------------------|-------------------|----------|---------|
| V. Strand et al., 2012 | Yes | Phase III RCT, double-blind | MTX-naive early RA | Mean 9 months | ≥8 swollen joints, ≥10 tender joints | Adalimumab 40mg EOW ± MTX | 104 weeks | Clinical trial, 133 sites in North America, Europe, Australia |
| B. Haraoui et al., 2011 | Yes | Multicenter, open-label, prospective single cohort | Active RA, 97.8% prior DMARD experience | Mean >12 years | Mean DAS28 6.1 | Adalimumab 40mg EOW + prior DMARDs | 12 weeks | Real-world, 69 sites across Canada |
| S. Bombardieri et al., 2007 | No | Open-label trial | Prior TNF antagonist exposure | Not mentioned | Not mentioned | Adalimumab 40mg EOW | 12 weeks with optional extension | Clinical trial |
| D. Pappas et al., 2017 | Yes | Observational registry | Biologic-naive adults with RA | Mean 7 years | Mean CDAI 19.9 | Not specified | Up to 12 years | Real-world, 170 sites across 40 US states |
| G. Burmester et al., 2014 | Yes | Phase 3b + postmarketing observational (ReAct/ReAlise) | Active RA, failed ≥1 DMARD | Not mentioned | Mean DAS28 6.0 | Adalimumab monotherapy or + DMARDs | Mean 1,016 days (5+ years) | Real-world, 10 European countries and Australia |
| L. B. A. Putte et al., 2003 | No | Phase II RCT, double-blind, placebo-controlled | DMARD-refractory, longstanding active RA | Longstanding | Not mentioned | Adalimumab 20/40/80mg weekly monotherapy | 12 weeks | Clinical trial |
| A. E. van der Bijl et al., 2008 | Yes | Prospective open-label pilot | Active RA, prior infliximab failure | Mean 12 years | DAS28 ≥3.2 | Adalimumab 40mg EOW + existing DMARDs | 16 weeks, maintenance to 56 weeks | Clinical trial |
| E. Keystone et al., 2014 | Yes | RCT with open-label extension (PREMIER OLE) | Early RA, disease duration <3 years | <3 years | DAS28 5.6 ± 1.7 | Initial: adalimumab 40mg EOW ± MTX; OLE: adalimumab with optional MTX | 2 years DB + 8 years OLE | Clinical trial, Australia, Europe, North America |
| D. Karateev et al., 2012 | No | Open-labeled multicenter | Active RA unresponsive to standard therapy | Not mentioned | DAS28-CRP 6.2 ± 0.84 | Adalimumab 40mg EOW + DMARDs | 24 weeks | Clinical trial, Russia |
| D. Furst et al., 2015 | No | Phase 3 open-label extension (DE020) | DMARD-refractory RA | Mean 11.7 years | Not mentioned | Adalimumab 40mg EOW or monthly | Up to 10 years | Clinical trial continuation |

### Clinical Effectiveness
#### Disease Activity and Response Rates
Clinical effectiveness varied by study duration and population characteristics. During short-term studies (12-24 weeks), ACR20 response rates ranged from 37% at 4 weeks to 88% at 24 weeks. At 12 weeks, ACR20 responses were achieved by 50.7-60% of patients, ACR50 by 27-33%, and ACR70 by 8-13%. Long-term studies demonstrated sustained or improved response rates.

#### Remission and Low Disease Activity
Using DAS28 <2.6 criteria, remission was achieved by 12-15.3% of patients at 12 weeks, increasing to 25% by 24 weeks. At year 10 with adalimumab plus MTX, DAS28 remission was achieved by 75.6%. Low disease activity (DAS28 <3.2) rates were achieved by 28.9% at 12 weeks in the CanACT study, increasing to 92.3% in the PREMIER extension.

#### Functional Outcomes
Functional status improved across studies, measured primarily by HAQ-DI. In long-term studies, a significant proportion achieved HAQ-DI <0.5, indicating improved functional status.

#### Radiographic Progression
Radiographic outcomes were assessed in long-term studies. Clinically relevant radiographic progression occurred in only one-third of patients receiving combination therapy, versus over half with monotherapy.

### Safety Outcomes
Safety data were reported across varying durations of exposure, from 12 weeks to over 5 years. Overall adverse event rates varied, with serious infections reported at rates of 2.4-2.8 events per 100 patient-years.

#### Patient-Reported Outcomes and Quality of Life
Health-related quality of life measures showed consistent improvements across studies. Pain assessments demonstrated substantial improvements, with significant reductions in pain scores observed across various studies.

### Synthesis
The included studies demonstrate considerable heterogeneity in design, duration, patient populations, and outcomes, yet several consistent patterns emerge regarding adalimumab's efficacy and safety in RA patients.